Premenopausal serum sex hormone levels in relation to breast cancer risk, overall and by hormone receptor status - Results from the EPIC cohort

International Journal of Cancer

Volumn 134, Issue 8, 2014, Pages 1947-1957

  Kaaks, Rudolf ^a   Tikk, Kaja ^a   Sookthai, Disorn ^a   Schock, Helena ^a   Johnson, Theron ^a   Tjønneland, Anne ^b   Olsen, Anja ^b   Overvad, Kim ^c   Clavel Chapelon, Françoise ^d,e,f   Dossus, Laure ^d,e,f   Baglietto, Laura ^g,h   Rinaldi, Sabina ⁱ   Chajes, Veronique ⁱ   Romieu, Isabelle ⁱ   Boeing, Heiner ^j   Schütze, Madlen ^j   Trichopoulou, Antonia ^k,l   Lagiou, Pagona ^k,m,n   Trichopoulos, Dimitrios ^l,m,n   Palli, Domenico ^o   Sieri, Sabina ^p   Tumino, Rosario ^q   Ricceri, Fulvio ^r,s   Mattiello, Amalia ^t   Buckland, Genevieve ^u   Ramón Quirós, Jose ^v   Sánchez, María José ^w,x,y   Amiano, Pilar ^y,z   Chirlaque, Maria Dolores ^y,aa   Barricarte, Aurelio ^y,ab   Bas Bueno De Mesquita, H ^ac,ad,ae   Van Gils, Carla H ^ad   Peeters, Petra H ^ad,ae   Andersson, Anne ^af   Sund, Malin ^ag   Weiderpass, Elisabete ^ah,ai,aj   Khaw, Kay Tee ^ak   Wareham, Nick ^al   Key, Timothy J ^am   Travis, Ruth C ^am   Merritt, Melissa A ^ae   Gunter, Marc J ^ae   Riboli, Elio ^ae   Lukanova, Annekatrin ^a,af   more..

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^c AARHUS UNIVERSITY   (Denmark)

^d CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^e UNIVERSITÉ PARIS SACLAY   (France)

^f IGR   (France)

^g CANCER EPIDEMIOLOGY CENTRE   (Australia)

^h UNIVERSITY OF MELBOURNE   (Australia)

ⁱ INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^j GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^k UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^l HELLENIC HEALTH FOUNDATION   (Greece)

^m HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

ⁿ BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^o CANCER RESEARCH AND PREVENTION INSTITUTE ISPO   (Italy)

^p NATIONAL CANCER INSTITUTE   (Italy)

^q CIVILE M P AREZZO HOSPITAL   (Italy)

^r Human Genetics Foundation   (Italy)

^s MAURIZIANO HOSPITAL   (Italy)

^t UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^u CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^v PUBLIC HEALTH DIRECTORATE   (Spain)

^w Andalusian School of Public Health   (Spain)

^x Instituto Biosanitario de Granada ibs GRANADA   (Spain)

^y Consortium for Biomed Res in Epidemiol ^*  (Spain)

^z Public Health Division of Gipuzkoa   (Spain)

^aa Murcia Regional Health Authority   (Spain)

^ab INSTITUTO DE SALUD PÚBLICA DE NAVARRA   (Spain)

^ac NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^ad UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^ae IMPERIAL COLLEGE LONDON   (United Kingdom)

^af UMEÅ UNIVERSITY   (Sweden)

^ag UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^ah UNIVERSITY OF TROMSØ   (Norway)

^ai University of Tromsø ^*  (Finland)

^aj KAROLINSKA INSTITUTE   (Sweden)

^ak UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^al MRC EPIDEMIOLOGY UNIT   (United Kingdom)

^am UNIVERSITY OF OXFORD   (United Kingdom)

more..

Author keywords

breast cancer; EPIC; estrogen receptor; prospective cohort; sex hormones

Indexed keywords

BREAST CANCER; EPIC; ESTROGEN RECEPTOR; PROSPECTIVE COHORT; SEX HORMONES;

ADULT; BREAST NEOPLASMS; CASE-CONTROL STUDIES; COHORT STUDIES; ESTRADIOL; FEMALE; GONADAL STEROID HORMONES; HUMANS; MALE; MIDDLE AGED; PREMENOPAUSE; PROGESTERONE; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE;

EID: 84893719571     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28528     Document Type: Article

References (46)

1. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997; 350: 1047-59.
2. Collaborative Group on Hormonal Factors in Breast Cancer. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol 2012; 13: 1141-51.
3. Kaaks R, Rinaldi S, Key TJ, et al. Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocr Relat Cancer 2005; 12: 1071-82. (Pubitemid 41815798)
4. James RE, Lukanova A, Dossus L, et al. Postmenopausal serum sex steroids and risk of hormone receptor-positive and -negative breast cancer: a nested case-control study. Cancer Prev Res (Phila) 2011; 4: 1626-35.
5. Sieri S, Krogh V, Bolelli G, et al. Sex hormone levels, breast cancer risk, and cancer receptor status in postmenopausal women: the ORDET Cohort. Cancer Epidemiol Biomarkers Prev 2009; 18: 169-76.
6. Zhang X, Tworoger S, Eliassen AH, et al. Postmenopausal plasma sex hormone levels and breast cancer risk over 20-years of follow-up. Breast Cancer Res Treat 2013; 137: 883-92.
7. Farhat GN, Cummings SR, Chlebowski RT, et al. Sex hormone levels and risks of estrogen receptor-negative and estrogen receptor-positive breast cancers. J Natl Cancer Inst 2011; 103: 562-70.
8. Zeleniuch-Jacquotte A, Shore RE, Koenig KL, et al. Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: long-term results of a prospective study. Br J Cancer 2004; 90: 153-9. (Pubitemid 38174955)
9. Helzlsouer KJ, Alberg AJ, Bush TL, et al. A prospective study of endogenous hormones and breast cancer. Cancer Detect Prev 1994; 18: 79-85. (Pubitemid 2077549)
10. Dorgan J, Stanczyk F, Kahle L, et al. Prospective case-control study of premenopausal serum estradiol and testosterone levels and breast cancer risk. Breast Cancer Res 2010; 12: R98.
11. Kaaks R, Berrino F, Key T, et al. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst 2005; 97: 755-65. (Pubitemid 40879595)
12. Thomas HV, Key TJ, Allen DS, et al. A prospective study of endogenous serum hormone concentrations and breast cancer risk in premenopausal women on the island of Guernsey. Br J Cancer 1997; 75: 1075-9. (Pubitemid 27122629)
13. Eliassen AH, Missmer SA, Tworoger SS, et al. Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J Natl Cancer Inst 2006; 98: 1406-15. (Pubitemid 44530717)
14. Fortner R, Eliassen AH, Spiegelman D, et al. Premenopausal endogenous steroid hormones and breast cancer risk: results from the Nurses' Health Study II. Breast Cancer Res 2013; 15: R19.
15. Zeleniuch-Jacquotte A, Afanasyeva Y, Kaaks R, et al. Premenopausal serum androgens and breast cancer risk: a nested case-control study. Breast Cancer Res 2012; 14: R32.
16. Rosenberg CR, Pasternack BS, Shore RE, et al. Premenopausal estradiol levels and the risk of breast cancer: a new method of controlling for day of the menstrual cycle. Am J Epidemiol 1994; 140: 518-25. (Pubitemid 24285934)
17. Micheli A, Muti P, Secreto G, et al. Endogenous sex hormones and subsequent breast cancer in premenopausal women. Int J Cancer 2004; 112: 312-18. (Pubitemid 39244371)
18. Schernhammer E, Sperati F, Razavi P, et al. Endogenous sex steroids in premenopausal women and risk of breast cancer: the ORDET cohort. Breast Cancer Res 2013; 15: R46.
19. Bingham S, Riboli E,. Diet and cancer-the European Prospective Investigation into Cancer and Nutrition. Nat Rev Cancer 2004; 4: 206-15. (Pubitemid 38337500)
20. Riboli E, Hunt KJ, Slimani N, et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr 2002; 5: 1113-24. (Pubitemid 36313608)
21. Riboli E, Kaaks R,. The EPIC Project: rationale and study design. European Prospective Investigation into Cancer and Nutrition. Int J Epidemiol 1997; 26 (Suppl 1): S6-S14. (Pubitemid 27129685)
22. Bergmann MM, Bussas U, Boeing H,. Follow-op procedures in EPIC-Germany-data quality aspects. Ann Nutr Metab 1999; 43: 225-34.
23. Vermeulen A, Verdonck L, Kaufman JM,. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999; 84: 3666-72. (Pubitemid 30645223)
24. Rinaldi S, Geay A, Dechaud H, et al. Validity of free testosterone and free estradiol determinations in serum samples from postmenopausal women by theoretical calculations. Cancer Epidemiol Biomarkers Prev 2002; 11: 1065-71. (Pubitemid 35192658)
25. Glynn RJ, Rosner B,. Methods to evaluate risks for composite end points and their individual components. J Clin Epidemiol 2004; 57: 113-22. (Pubitemid 38678613)
26. Rothman KJ, Greenland S, Lash TL,. Modern epidemiology, 3rd edn. Philadelphia, PA: Lippincott, Williams & Wilkins, 2008. 279p, 425 p.
27. Missmer SA, Spiegelman D, Bertone-Johnson ER, et al. Reproducibility of plasma steroid hormones, prolactin, and insulin-like growth factor levels among premenopausal women over a 2- to 3-year period. Cancer Epidemiol Biomarkers Prev 2006; 15: 972-8. (Pubitemid 43823526)
28. Micheli A, Muti P, Pisani P, et al. Repeated serum and urinary androgen measurements in premenopausal and postmenopausal women. J Clin Epidemiol 1991; 44: 1055-61.
29. Nelson VL, Legro RS, Strauss JF, III, et al. Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries. Mol Endocrinol 1999; 13: 946-57. (Pubitemid 30645312)
30. Micheli A, Muti P, Pisani P, et al. Repeated serum and urinary androgen measurements in premenopausal and postmenopausal women. J Clin Epidemiol 1991; 44: 1055-61.
31. Davison SL, Bell R, Donath S, et al. Androgen levels in adult females: changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab 2005; 90: 3847-53. (Pubitemid 41058142)
32. Burger HG, Hale GE, Robertson DM, et al. A review of hormonal changes during the menopausal transition: focus on findings from the Melbourne Women's Midlife Health Project. Hum Reprod Update 2007; 13: 559-65. (Pubitemid 350018524)
33. Doisneau-Sixou SF, Sergio CM, Carroll JS, et al. Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells. Endocr Relat Cancer 2003; 10: 179-86. (Pubitemid 36758647)
34. Dickson RB, Stancel GM,. Chapter 8: estrogen receptor-mediated processes in normal and cancer cells. JNCI Monogr 2000; 2000: 135-45.
35. Dimitrakakis C, Zhou J, Bondy CA,. Androgens and mammary growth and neoplasia. Fertil Steril 2002; 77 (Suppl 4): S26-S33. (Pubitemid 34465841)
36. Liao DJ, Dickson RB,. Roles of androgens in the development, growth, and carcinogenesis of the mammary gland. J Steroid Biochem Mol Biol 2002; 80: 175-89. (Pubitemid 34233739)
37. Xie B, Tsao SW, Wong YC,. Sex hormone-induced mammary carcinogenesis in female noble rats: the role of androgens. Carcinogenesis 1999; 20: 1597-606. (Pubitemid 29385451)
38. Xie B, Tsao SW, Wong YC,. Induction of high incidence of mammary tumour in female Noble rats with a combination of 17beta-oestradiol and testosterone. Carcinogenesis 1999; 20: 1069-78. (Pubitemid 29263753)
39. Hickey TE, Robinson JLL, Carroll JS, et al. Minireview: the androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene? Mol Endocrinol 2012; 26: 1252-67.
40. Garay JP, Park BH,. Androgen receptor as a targeted therapy for breast cancer. Am J Cancer Res 2012; 2: 434-45.
41. Labrie F, Luu-The V, Labrie C, et al. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev 2003; 24: 152-82. (Pubitemid 36515283)
42. Nicolas Diaz-Chico B, German Rodriguez F, Gonzalez A, et al. Androgens and androgen receptors in breast cancer. J Steroid Biochem Mol Biol 2007; 105: 1-15. (Pubitemid 47214620)
43. Wysowski DK, Comstock GW, Helsing KJ, et al. Sex hormone levels in serum in relation to the development of breast cancer. Am J Epidemiol 1987; 125: 791-9. (Pubitemid 17066478)
44. Kabuto M, Akiba S, Stevens RG, et al. A prospective study of estradiol and breast cancer in Japanese women. Cancer Epidemiol Biomarkers Prev 2000; 9: 575-9. (Pubitemid 30396179)
45. Magne N, Toillon RA, Castadot P, et al. Different clinical impact of estradiol receptor determination according to the analytical method: a study on 1940 breast cancer patients over a period of 16 consecutive years. Breast Cancer Res Treat 2006; 95: 179-84.
46. von Wasielewski R, Mengel M, Wiese B, et al. Tissue array technology for testing interlaboratory and interobserver reproducibility of immunohistochemical estrogen receptor analysis in a large multicenter trial. Am J Clin Pathol 2002; 118: 675-82. (Pubitemid 37046311)